The PennZone

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech, Inc. (Nasdaq:KRYS) today announced that Chief Commercial Officer Jennifer Chien is leaving the company, effective today, to pursue another opportunity. Senior members of Krystal's commercial team will report directly to Chief Executive Officer Krish Krishnan on an interim basis as the company initiates a search for Ms. Chien's replacement.

"I look forward to working with our commercial leadership team and expect continued progress of our pre-launch activities without interruption," said Krish Krishnan, Chief Executive Officer, Krystal Biotech. "Our GEM-3 trial is advancing as planned and we anticipate completing enrollment early next year. While the COVID-19 environment has been a challenge to everyone in the industry, I am pleased that our careful planning has kept patient enrollment on track across diverse geographical sites in the US."

About Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS) is a gene therapy company dedicated to developing transformative medicines to treat diseases caused by protein or gene dysfunction. For more information, please visit http://www.krystalbio.com.

More on The PennZone

• Chuckie F. Mahoney Memorial Foundation Awards Nearly $40,000 in School Grants
• OPUS Global Data Solutions Launches Food Trader Plus, Bringing Operational Control and Deal-Level Profit Visibility to Food Brokers
• Phinge CEO DeMaio Unveils Speech to Congress: User Data Sovereignty vs Tech Surveillance Capitalism, Asserting Foundational 2021 App-Less Patents & IP
• Michael Maertens Hired as Century Fasteners Corp. – Chief Financial Officer
• LATO AI Software Innovations Expedite Inspections & Repair of Parking Lots for The Pavement Group

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., including but not limited to statements about the development of Krystal's product candidates, such as plans for the design, conduct and timelines of ongoing clinical trials of beremagene geperpavec ("B-VEC"), KB105, KB104, KB301 and KB407; the clinical utility of B-VEC, KB105, KB104, KB301 and KB407, and Krystal's plans for filing of regulatory approvals and efforts to bring B-VEC, KB105, KB104, KB301 and KB407 to market; the market opportunity for and the potential market acceptance of B-VEC, KB105, KB104, KB301 and KB407; plans to pursue research and development of other product candidates; the sufficiency of Krystal's existing cash resources; the unanticipated impact of COVID-19 on Krystal's business operations, pre-clinical activities and clinical trials; and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "likely," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or trials will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of product candidates including B-VEC, KB105, KB104, KB301 and KB407, the sufficiency of cash resources and need for additional financing and such other important factors as are set forth under the caption "Risk Factors" in Krystal's annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal's views as of the date of this release. Krystal anticipates that subsequent events and developments will cause its views to change. However, while Krystal may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal's views as of any date subsequent to the date of this release.

More on The PennZone

• Built to Last: Why BSI Is Among the Nation's Fastest-Growing Companies, and One of Its Best Places to Work
• Bent Danholm's The Architecture of Demand Reaches No. 2 in Amazon Real Estate Sales
• Contracting Resources Group Named to Inc. 5000 for the Ninth Time
• Nola Blue Records to Release John Németh's Illinois Central in March 2027
• ImagineX Named to 2026 Inc. 5000 List of America's Fastest-Growing Private Companies

---

Show All News | Disclaimer | Report Violation